



## Índice numérico

### Comunicações orais

- CO 1 SINUS RHYTHM ENDOCARDIAL MAPPING FOR CHANNELS' IDENTIFICATION IN ISCHEMIC VENTRICULAR TACHYCARDIA USING A MODIFIED ELECTROPHYSIOLOGICAL TRIAD
- CO 2 ASSESSMENT OF WAVEFRONT ACTIVATION DURATION ACROSS THE RIGHT VENTRICULAR OUTFLOW TRACT IN PATIENTS WITH IDIOPATHIC PREMATURE VENTRICULAR CONTRACTIONS USING NONINVASIVE ELECTROCARDIOGRAPHIC MAPPING: A VALIDATION STUDY
- CO 3 LATE GADOLINIUM ENHANCEMENT IS A STRONG PREDICTOR OF LIFE-THREATENING ARRHYTHMIAS IN PATIENTS WITH NON-ISCHEMIC DILATED CARDIOMYOPATHY UNDERGOING ICD IMPLANTATION FOR PRIMARY PREVENTION OF SUDDEN CARDIAC DEATH
- CO 4 IS IT POSSIBLE TO PREDICT MORTALITY AND RECURRENCE OF VT AFTER ABLATION? - PAINESD RISK SCORE APPLICABILITY VS NEW PREDICTORS
- CO 5 EPICARDIAL MAPPING AS FIRST INTENTION APPROACH FOR STRUCTURAL VENTRICULAR TACHYCARDIA ABLATION
- CO 6 ACUTE MYOCARDIAL INFARCTION DURING COVID-19 ERA: PATIENT CHARACTERISTICS, PRESENTATION AND OUTCOMES
- CO 7 STEMI WITH MID-RANGE EJECTION FRACTION - A GROUP OF INTERMEDIATE RISK NOT TO BE FORGOTTEN
- CO 8 PRECISE-DAPT SCORE FOR BLEEDING PREDICTION AFTER ACUTE CORONARY SYNDROME IN PATIENTS TREATED WITH PERCUTANEOUS CORONARY INTERVENTION FOR MULTIVESSEL DISEASE
- CO 9 RESUSCITATED CARDIAC ARREST IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION IS ASSOCIATED WITH INCREASED INFARCT SIZE AND WORSE OUTCOMES
- CO 10 SGLT2 INHIBITION IN ACUTE MYOCARDIAL INFARCTION WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION
- CO 11 REVERSE LEFT VENTRICULAR REMODELING AFTER AORTIC VALVE REPLACEMENT FOR AORTIC STENOSIS: SYSTEMATIC REVIEW AND META-ANALYSIS
- CO 12 A PRELIMINARY ANALYSIS REGARDING FUNCTIONAL MITRAL REGURGITATION GRADING WITH ECHOCARDIOGRAPHY AND CMR: IN SEARCH OF SIMILARITIES AND RESOLVING DISCORDANCES.
- CO 13 CLINICAL AND ECHOCARDIOGRAPHIC VERY LONG-TERM OUTCOMES AFTER PERCUTANEOUS MITRAL BALLOON VALVULOPLASTY IN SEVERE RHEUMATIC MITRAL STENOSIS
- CO 14 PERCUTANEOUS VALVE COMMISSUROTOMY FOR MITRAL STENOSIS PATIENTS: A 20 YEARS FOLLOW-UP
- CO 15 CONTRACTILE RESERVE: A KEY FACTOR IN AORTIC STENOSIS
- CO 16 ACUTE PULMONARY EMBOLISM CATHETER-DIRECTED THERAPY: FIRST RESULTS OF A MULTIPARAMETRIC FOLLOW-UP PROTOCOL
- CO 17 COMPERA SCORE REVISED: BETTER RISK ESTIMATION TO BETTER TAILOR THERAPEUTICS IN PRECAPILLARY HYPERTENSION.
- CO 18 MULTIDIMENSIONAL CT APPROACH TO PREDICT HEMODYNAMICS IN PULMONARY HYPERTENSION
- CO 19 PULMONARY HYPERTENSION IN CONNECTIVE TISSUE DISEASES WITH OVERT OF FEATURES OF VENOUS/CAPILLARIES INVOLVEMENT: CLINICAL IMPLICATIONS AND PROGNOSTIC IMPACT OF THIS PHENOTYPE.

- CO 20 RIGHT HEART REMODELING AFTER BALLOON PULMONARY ANGIOPLASTY IN PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
- CO 21 POTENTIAL IMPACT OF REPLACING SCORE WITH SCORE-2 ON RISK CLASSIFICATION AND STATIN ELIGIBILITY - A CORONARY CALCIUM SCORE CORRELATION STUDY
- CO 22 THE EVALUATION OF THE EUROPEAN SCORE2 IN A PORTUGUESE POPULATION
- CO 23 PROGNOSTIC IMPACT OF ADDING CORONARY CALCIUM SCORE TO EUROPEAN SCORE2 IN AN ASYMPTOMATIC PORTUGUESE POPULATION
- CO 24 PROGNOSTIC ROLE OF ADDING A GENETIC RISK SCORE TO THE NEW EUROPEAN SCORE2 IN CARDIOVASCULAR EVENTS PREDICTION, IN A MODERATE-RISK REGION
- CO 25 A NEW SCORE MODEL FOR MORTALITY PREDICTION IN TREADMILL TEST
- CO 26 PATIENT DELAY IN ACUTE MYOCARDIAL INFARCTION - A LONG JOURNEY STILL AHEAD
- CO 27 CORONARY SINUS REDUCER DEVICE FOR THE TREATMENT OF REFRACTORY ANGINA THERAPY. A MULTICENTRIC INITIAL EXPERIENCE.
- CO 28 PERIPHERAL VENOARTERIAL EXTRACORPOREAL MEMBRANE OXYGENATION FOR REFRACTORY CARDIOGENIC SHOCK: SINGLE-CENTER EXPERIENCE
- CO 29 CIRCADIAN RHYTHM IMPACT IN REMOTE ISCHEMIC CONDITIONING IN MYOCARDIAL INFARCTION
- CO 30 EFFECTIVENESS AND SAFETY OF P2Y12 INHIBITOR PRETREATMENT FOR PRIMARY PCI IN STEMI: SYSTEMATIC REVIEW AND META-ANALYSIS
- CO 31 VALVE-IN-VALVE TAVI FOR FAILING SURGICAL AORTIC BIOPROSTHETIC VALVES: A SINGLE-CENTRE EXPERIENCE
- CO 32 TRANSCATHETER AORTIC VALVE DESIGN AND MORTALITY: TRUTH OR REALITY?
- CO 33 VASCULAR CLOSURE DEVICE IN TAVI WITH A DEDICATED ENDOVASCULAR PLUG-BASED DEVICE. EXPERIENCE FROM A HIGH-VOLUME TERTIARY CENTER
- CO 34 EARLY AORTIC VALVE REPLACEMENT VERSUS CONSERVATIVE MANAGEMENT IN ASYMPTOMATIC SEVERE AORTIC STENOSIS
- CO 35 META-ANALYSIS COMPARING OUTCOMES IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE IMPLANTATION WITH VERSUS WITHOUT PERCUTANEOUS CORONARY INTERVENTION
- CO 36 PROGNOSTIC IMPACT OF PERCENTAGE OF VENTRICULAR PACING IN PATIENTS REQUIRING PACEMAKER IMPLANTATION AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT
- CO 37 HEART RATE SCORE: A SIMPLE AND USEFUL PREDICTOR FOR CLINICAL OUTCOMES IN HEART FAILURE
- CO 38 WHAT IS THERE TO EARN WITH A CRT IMPLANTATION? PREDICTIVE FACTORS OF MORTALITY OR CLINICAL DETERIORATION IN PATIENTS RECEIVING CARDIAC RESYNCHRONIZATION THERAPY BASED ON PRE-IMPLANT FACTORS.
- CO 39 PACING VENTRICULAR NA REGIÃO DO RAMO ESQUERDO - EXPERIÊNCIA INICIAL
- CO 40 APICAL VERSUS SEPTAL PACING AND UPGRADE TO CARDIAC RESYNCHRONIZATION THERAPY: WHAT ARE THE ODDS?
- CO 41 A DECADE OF EXPERIENCE WITH ROTATIONAL ATERECTOMY: A SINGLE-CENTRE STUDY
- CO 42 RESIDUAL SHUNT AFTER PATENT FORAMEN OVALE CLOSURE: PREDICTORS' AND ITS IMPACT ON LONG-TERM OUTCOMES
- CO 43 PERCUTANEOUS LEFT ATRIAL APPENDAGE CLOSURE: A SINGLE CENTER EXPERIENCE
- CO 44 3D PRINTING FOR LEFT ATRIAL APPENDAGE CLOSURE: A META-ANALYSIS OF COHORT STUDIES
- CO 45 ISCHEMIC HEART DISEASE: LOOKING BEYOND CORONARY STENOSIS
- CO 46 REMOTE INVASIVE MONITORING OF PULMONARY ARTERY PRESSURE IN PATIENTS WITH HEART FAILURE: INITIAL EXPERIENCE OF A TERTIARY CARE CENTER
- CO 47 BNP VERSUS NT-PROBNP FOR ECHOCARDIOGRAPHIC AND HEMODYNAMIC PARAMETERS PREDICTION IN HEART TRANSPLANTED PATIENTS
- CO 48 NT-PROBNP FOR FUNCTIONAL CAPACITY ASSESSMENT IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
- CO 49 CAN ECHOCARDIOGRAPHIC PARAMETERS EFFECTIVELY PREDICT ELEVATED PCWP IN HEART TRANSPLANT PATIENTS?
- CO 50 LONG-TERM BENEFITS OF NON-INVASIVE TELEMONITORING IN PATIENTS WITH CHRONIC HEART FAILURE
- CO 51 USE OF CORONARY CALCIUM SCORE TO REFINE THE CARDIOVASCULAR RISK CLASSIFICATION OF THE NEW SCORE-2 AND SCORE-2 OP ALGORITHMS IN PATIENTS UNDERGOING CORONARY CT ANGIOGRAPHY
- CO 52 INDEXING CALCIUM SCORE OF THE AORTIC VALVE TO THE ANNULUS AREA IMPROVES THE GRADING OF AORTIC STENOSIS SEVERITY IN PATIENTS WITHIN THE "GREY ZONE" OF AORTIC VALVE CALCIFICATION
- CO 53 LATE GADOLINIUM ENHANCEMENT PATTERNS IN SEVERE SYMPTOMATIC HIGH-GRADIENT AORTIC STENOSIS

- CO 54 99MTC-DPD SCINTIGRAPHY IN THE DIAGNOSIS AND PROGNOSIS OF TRANSTHYRETIN V30M CARDIAC AMYLOIDOSIS
- CO 55 LEFT VENTRICULAR REMODELING IN AORTIC STENOSIS PATIENTS REFERRED FOR SURGICAL AORTIC VALVE REPLACEMENT
- CO 56 CARDIAC RESYNCHRONIZATION THERAPY IN ATRIAL FIBRILLATION: RESPONSE AND LONG-TERM OUTCOMES
- CO 57 ONLY RIGHT VENTRICULAR FUNCTION PARAMETERS CAN PREDICT ACUTE CELLULAR REJECTION IN HEART TRANSPLANT PATIENTS?
- CO 58 THE EFFECT OF HEART FAILURE THERAPY IN PATIENTS WITH MILDLY REDUCED EJECTION FRACTION: A NETWORK META-ANALYSIS
- CO 59 HEART FAILURE WITH REDUCED EJECTION FRACTION FOUNDATIONAL THERAPY: WHY SHOULD WE FOLLOW THE 2021 EUROPEAN SOCIETY OF CARDIOLOGY HEART FAILURE GUIDELINES AND FORGET THE PREVIOUS THERAPEUTIC ALGORITHM?
- CO 60 MAIN LIMITING FACTORS OF FOUNDATIONAL THERAPY INTRODUCTION IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
- CO 61 ATRIAL GANGLIONATED PLEXI MODIFICATION COMBINED WITH PULMONARY VEIN ISOLATION IN ATHLETES WITH HIGHLY SYMPTOMATIC ATRIAL FIBRILLATION AND BASELINE BRADYCARDIA
- CO 62 NOT SUCH A BLANKING PERIOD AFTER ALL: EARLY RECURRENCE PREDICTS LATE RECURRENCE AFTER AF ABLATION
- CO 63 FLUOROLESS CAVOTRICUSPID ISTHMUS ABLATION SUCCESSFULLY ACHIEVES ATRIAL FLUTTER CONTROL
- CO 64 CRYO-3D - A THREE-DIMENSIONAL MAPPING-GUIDED CRYOBALLOON-BASED ATRIAL FIBRILLATION ABLATION: FEASIBILITY AND PRELIMINARY RESULTS
- CO 65 ISOLATION OF PULMONARY VEINS WITH DUTY-CYCLED CIRCULAR MULTI-POLAR CATHETER
- CO 66 CARDIOGENIC SHOCK COMPLICATING ACUTE MYOCARDIAL INFARCTION DUE TO LEFT MAIN CORONARY ARTERY OCCLUSION: A MULTICENTRE STUDY
- CO 67 CARDIAC ARREST IN PATIENTS WITH ACUTE LEFT MAIN STEM OCCLUSION: A REAL-WORLD MULTICENTER REGISTRY
- CO 68 ACUTE TOTAL OCCLUSION OF THE UNPROTECTED LEFT MAIN CORONARY ARTERY - PATIENT CHARACTERISTICS AND OUTCOMES
- CO 69 MECHANICAL CIRCULATORY SUPPORT DEVICES IN LEFT MAIN OCCLUSION: A MULTICENTER STUDY FROM 2008 TO 2020
- CO 70 AMI DUE TO LEFT MAIN CORONARY ARTERY OCCLUSION: A COMPARATIVE MULTICENTER STUDY FROM 2008 TO 2020
- CO 71 PERCEPTION OF NOISE IN A CICU: IMPLICATIONS ON THE WELL-BEING OF PERSON IN CRITICAL SITUATION
- CO 72 TÉCNICOS DE CARDIOPNEUMOLOGIA NO SERVIÇO DE URGÊNCIA NA PRESTAÇÃO DE CUIDADOS AOS DOENTES COM SÍNDROME CORONÁRIA AGUDA
- CO 73 VASCULAR REMODELLING DURING PREGNANCY AND POSTPARTUM
- CO 74 + CORAÇÃO + VIDA: MAIOR ARTICULAÇÃO E VIGILÂNCIA DO UTENTE COM PATOLOGIA CARDIOVASCULAR E SUAS FAMÍLIAS
- CO 75 IMPACTO DA INTERVENÇÃO DO ENFERMEIRO DE REABILITAÇÃO NA REDUÇÃO DOS REINTERNAMENTOS POR INSUFICIÊNCIA CARDÍACA AOS 30 DIAS
- CO 76 PREVALENCE OF RV DYSFUNCTION IN PATIENTS UNDER CARDIOTOXIC CHEMOTERAPY: A PRELIMINARY ANALYSIS
- CO 77 CARDIOTOXICITY IN BREAST CANCER PATIENTS - RISK FACTORS AND ROLE OF CARDIOPROTECTIVE DRUGS
- CO 78 THE IMPACT OF COMORBIDITIES IN CARDIAC REMODELLING AND REVERSE REMODELLING INDUCED BY PREGNANCY
- CO 79 CARDIOPULMONARY EXERCISE TESTING IN FONTAN PATIENTS: UNMASKING THE SECRET OF "SUPER-FONTANS"
- CO 80 COMPARISON OF DIFFERENT CLINICAL PROGNOSTIC SCORES IN PATIENTS WITH PULMONARY EMBOLISM AND ACTIVE CANCER
- CO 81 HISTOLOGY-VERIFIED MYOCARDIAL FIBROSIS IN SEVERE AS PATIENTS: PREVALENCE AND CORRELATION WITH NON-INVASIVE LV MYOCARDIAL TISSUE ASSESSMENT
- CO 82 TRANSCRIPTION FACTOR 21 AND PROGNOSIS IN A CAD POPULATION
- CO 83 PLASMA LIPIDOMICS IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION
- CO 84 THERAPEUTIC EFFECT OF UROCORTIN-2 IN HEART FAILURE WITH PRESERVED EJECTION FRACTION
- CO 85 APPLICATION OF ARTIFICIAL INTELLIGENCE IN CORONARY CT ANGIOGRAPHY: A POTENTIAL GATEKEEPER STRATEGY?
- CO 86 CORRELATION BETWEEN NSTEMI-ACS RISK SCORES WITH SYNTAX: CAN WE PREDICT CORONARY LESION COMPLEXITY BEFORE ANGIOGRAPHY?
- CO 87 NEW-ONSET OF ATRIAL FIBRILLATION IN ST-ELEVATION MYOCARDIAL INFARCTION

- CO 88 FUNCTIONAL IRON DEFICIENCY IN ACUTE CORONARY SYNDROMES: PREVALENCE AND PROGNOSTIC IMPACT
- CO 89 WORKLOAD-INDEXED BLOOD PRESSURE RESPONSE PREDICTS CARDIOVASCULAR EVENTS IN CORONARY ARTERY DISEASE
- CO 90 LONG-TERM PROGNOSIS OF MYOCARDIAL INFARCTION WITH NON-OBSTRUCTIVE CORONARY ARTERIES VERSUS MYOCARDIAL INFARCTION WITH OBSTRUCTIVE CORONARY ARTERY DISEASE
- CO 91 SEGMENTAL ANALYSIS OF MICROVASCULAR DYSFUNCTION AND TISSUE CHARACTERIZATION IN HYPERTROPHIC CARDIOMYOPATHY BY MAGNETIC RESONANCE IMAGING
- CO 92 TRANSCATHETER AORTIC VALVE IMPLANTATION OUTCOMES IN PATIENTS WITH LOW FLOW - LOW GRADIENT AORTIC STENOSIS
- CO 93 IMPLICATIONS OF THE NORTH AMERICAN 2021 CHEST PAIN GUIDELINES IN THE DIAGNOSTIC APPROACH TO PATIENTS WITH STABLE CHEST PAIN AND LOW PRETEST PROBABILITY OF OBSTRUCTIVE CORONARY ARTERY DISEASE
- CO 94 FUNCTIONAL MITRAL REGURGITATION: KEEPING COHERENCE WITH THE ASE GRADING GUIDELINES, WHICH PROPORTIONALITY CONCEPT BEST PREDICTS PROGNOSIS IN THE REAL WORLD?
- CO 95 DEVELOPMENT OF DEEP LEARNING SEGMENTATION MODELS FOR CORONARY X-RAY ANGIOGRAPHY: PERFORMANCE ASSESSMENT BY NEW CLINICAL CRITERIA SCORE AND COMPARISON WITH HUMAN PERFORMANCE
- CO 96 LEFT VENTRICULAR STRAIN IMAGING IN HEART FAILURE PATIENTS UNDER SACUBITRIL/VALSARTAN THERAPY
- CO 97 SAFETY AND EFFECTIVENESS OF SACUBITRIL-VALSARTAN IN A REAL-WORLD POPULATION
- CO 98 SACUBITRIL-VALSARTAN VERSUS ACEI IN LEFT VENTRICULAR REVERSE REMODELLING AND CARDIOVASCULAR OUTCOMES
- CO 99 DOES DAPAGLIFLOZIN IMPROVE CARDIOPULMONARY PERFORMANCE OF NON-DIABETIC HEART FAILURE PATIENTS?
- CO 100 SGLT2 INHIBITOR INITIATION IN PATIENTS HOSPITALIZED FOR ACUTE HEART FAILURE: DOES IT STILL MATTER WHEN PATIENTS ARE STRICTLY FOLLOWED AFTER DISCHARGE?
- CO 101 PERCUTANEOUS BALLOON MITRAL VALVULOPLASTY FOR MITRAL STENOSIS PATIENTS: AN OLD BUT RELIABLE WEAPON
- CO 102 PREDICTORS OF FUNCTIONAL RECOVERY AFTER MITRAL TRANSCATHETER-EDGE-TO-EDGE REPAIR
- CO 103 REFINING PATIENT SELECTION TO PERCUTANEOUS MITRAL VALVE REPAIR IN SECONDARY MITRAL REGURGITATION
- CO 104 IMPACT OF RESIDUAL SIGNIFICANT MITRAL REGURGITATION IN TAVR PATIENTS
- CO 105 CAROTID ANGIOPLASTY STENTING VERSUS ENDARTERECTOMY VERSUS BEST MEDICAL TREATMENT - WHAT IS THE BEST STRATEGY FOR THE TREATMENT OF CAROTID STENOSIS?
- CO 106 ACCURACY OF NONINVASIVE ELECTROCARDIOGRAPHIC IMAGING USING ISOPOTENTIAL VERSUS ISOCHRONAL MAP FOR IDENTIFYING THE SITE OF ORIGIN OF VENTRICULAR ARRHYTHMIAS.
- CO 107 HIGHER CORONARY CALCIUM SCORE IS ASSOCIATED WITH INCREASED RISK OF ATRIAL FIBRILLATION RECURRENCE
- CO 108 PREVALENCE AND IMPACT OF TACHYARRHYTHMIAS IN PATIENTS ADMITTED WITH COVID-19 PNEUMONIA
- CO 109 CARDIONEUROABLATION OF NEURALLY MEDIATED REFLEX SYNCOPE: THE EXPERIENCE OF TWO PORTUGUESE CENTRES
- CO 110 USEFULNESS OF THE NON-INVASIVE ASSESSMENT OF LATE POTENTIALS FOR RISK STRATIFICATION IN BRUGADA SYNDROME
- CO 111 ECHOCARDIOGRAPHIC OUTCOMES OF OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY AFTER PERCUTANEOUS ASA: A SINGLE CENTRE EXPERIENCE
- CO 112 THREE DIMENSIONAL MYOCARDIAL DEFORMATION PARAMETERS ARE ASSOCIATED WITH FUNCTIONAL CAPACITY IN HYPERTROPHIC CARDIOMYOPATHY
- CO 113 MICROVASCULAR DYSFUNCTION IS ASSOCIATED WITH IMPAIRED MYOCARDIAL WORK IN OBSTRUCTIVE AND NONOBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: A MULTIMODALITY APPROACH
- CO 114 MYOCARDIAL DEFORMATION ANALYSIS USING CARDIAC MAGNETIC RESONANCE IN APICAL HYPERTROPHIC CARDIOMYOPATHY
- CO 115 REDUCED 3D-LEFT ATRIUM EJECTION FRACTION PREDICTS DEVELOPMENT OF ATRIAL FIBRILLATION IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY
- CO 116 PREGNANCY OUTCOMES IN WOMEN WITH SEVERE CONGENITAL HEART DISEASE - A SPECIALIZED CENTRE EXPERIENCE
- CO 117 IMPACT OF COVID-19 IN ADULT PATIENTS WITH CONGENITAL HEART DISEASE
- CO 118 CARDIOPULMONARY EXERCISE TESTING IN REPAIRED TETRALOGY OF FALLOT AND SUPRAVENTRICULAR ARRHYTHMIAS
- CO 119 BETA-BLOCKERS: A MODIFIER OF THE NATURAL HISTORY OF BICUSPID AORTIC VALVES?
- CO 120 THE WORLD UPSIDE DOWN - AFTER 20 YEARS FOLLOW-UP OF DEXTRO-TRANSPOSITION OF THE GREAT ARTERIES
- CO 121 CARDIAC REHABILITATION AND MUSCLE EFFICIENCY IMPROVEMENT IN HEART FAILURE PATIENTS

- CO 122 IMPACT OF CARDIAC REHABILITATION ON INFLAMMATION IN PATIENTS WITH ISCHAEMIC CARDIOMYOPATHY
- CO 123 IS THE OBESITY PARADOX LEADING TO A LESS STRINGENT SECONDARY PREVENTION STRATEGY IN PATIENTS WHO HAVE SUSTAINED AN ACUTE CORONARY SYNDROME?
- CO 124 SYNERGISM OF TWO ACE GENE VARIANTS IN THE ONSET OF HYPERTENSION IN A PORTUGUESE POPULATION
- CO 125 EFFECTS OF HOME-BASED ISOMETRIC HANDGRIP TRAINING IN OLDER ADULTS WITH HIGH BLOOD PRESSURE
- CO 126 TRANSTHYRETIN AMYLOID CARDIOMYOPATHY: A 2-YEAR SINGLE-CENTRE EXPERIENCE
- CO 127 I NEED HELP: FROM THE ACRONYM TO THE RISK SCORE FOR PREDICTING ADVERSE OUTCOMES IN CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION
- CO 128 CARDIORENAL SYNDROME AND DEATH RISK IN PATIENTS WITH HEART FAILURE OR CHRONIC KIDNEY DISEASE: AN UNMET CARDIORENAL NEED?
- CO 129 EXERCISE OSCILLATORY VENTILATION - IS THERE MORE TO IT THAN JUST UPS AND DOWNS?
- CO 130 MODIFIED VERSUS CONVENTIONAL BODY MASS INDEX IN PATIENTS ADMITTED DUE TO ACUTE HEART FAILURE: ASSOCIATION WITH ADVERSE PROGNOSIS.
- CO 131 REGIONAL IMPAIRMENT OF LEFT VENTRICULAR LONGITUDINAL STRAIN IN AORTIC REGURGITATION - HAVE WE FOUND THE MISSING PIECE?
- CO 132 A CMR MYOCARDIAL STRAIN PATTERNS ANALYSIS IN LEFT BUNDLE BRANCH BLOCK
- CO 133 RELATIVE APICAL SPARING IN SEVERE AORTIC STENOSIS: DOES IT MEAN CONCOMITANT AMYLOID CARDIOMYOPATHY?
- CO 134 LEFT ATRIAL STRAIN ANALYSIS IN PATIENTS WITH SEVERE RHEUMATIC MITRAL STENOSIS SUBMITTED TO MITRAL BALLOON VALVULOPLASTY
- CO 135 PROGNOSTIC VALUE OF GLOBAL LONGITUDINAL STRAIN IN PATIENTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
- CO 136 RISK STRATIFICATION IN PULMONARY ARTERIAL HYPERTENSION: DO OUR PATIENTS BENEFIT FROM A 4-STRATA MODEL?
- CO 137 FOLLOW-UP OF CHILDREN WITH BRUGADA SYNDROME: EXPERIENCE FROM A TERTIARY PAEDIATRIC REFERRAL CENTRE
- CO 138 THORS SCORE, A BETTER PREDICTOR OF IN-HOSPITAL AND LONG-TERM MORTALITY AFTER ACUTE PULMONARY EMBOLISM?
- CO 139 ACUTE PULMONARY EMBOLISM CATHETER-DIRECTED THERAPY: A SAFETY AND FEASIBILITY ANALYSIS
- CO 140 CARDIOPULMONARY EXERCISE TESTING IN REPAIRED TETRALOGY OF FALLOT AND RIGHT VENTRICLE DILATATION
- CO 141 MICROVASCULAR DYSFUNCTION AND MYOCARDIAL FIBROSIS IMPACT ON LEFT VENTRICULAR MYOCARDIAL DEFORMATION IN HYPERTROPHIC CARDIOMYOPATHY - PER SEGMENT ANALYSIS BY MAGNETIC RESONANCE IMAGING
- CO 142 MECHANICAL DISPERSION: CAN IT PREDICT THE OCCURRENCE OF VENTRICULAR ARRHYTHMIAS IN FABRY DISEASE?
- CO 143 CLINICAL AND ECHOCARDIOGRAPHIC PROGNOSTIC FACTORS IN WILD TYPE TRANSTHYRETIN CARDIAC AMYLOIDOSIS
- CO 144 DOES MY TAVR PATIENT HAVE CARDIAC AMYLOIDOSIS?
- CO 145 MYOCARDITIS, PERICARDITIS AND COVID-19 VACCINATION - A TRUE CONCERN?
- CO 146 BIOLOGICAL OR MECHANICAL AORTIC PROSTHESES IN PATIENTS AGED 40-60 YEARS : A SINGLE CENTRE EXPERIENCE
- CO 147 MIECTOMIA MORROW NA MIOCARDIOPATIA HIPETRÓFICA OBSTRUTICA: RESULTADOS A CURTO E LONGO PRAZO DE UM CENTRO REFERÊNCIA

## Posters

- PO 1 CARDIAC FAT AND MICROCALCIFICATION AS SURROGATE MARKERS OF CORONARY ATHEROGENESIS
- PO 2 ASSOCIATION OF EPICARDIAL FAT AND CORONARY ARTERY CALCIUM SCORE IN PATIENTS WITH ATRIAL FIBRILLATION
- PO 3 GENDER-SPECIFIC DIFFERENCES IN OBSTRUCTIVE CORONARY ARTERY DISEASE BY CORONARY CT ANGIOGRAPHY
- PO 4 LOW CORONARY CALCIUM SCORE IN PATIENTS WITH OBSTRUCTIVE CORONARY DISEASE
- PO 5 ARTIFICIAL INTELLIGENCE-ENABLED COMPREHENSIVE CORONARY PHENOTYPING IN PATIENTS WITH SUSPECTED CAD
- PO 6 BENEFIT OF SLEEP STUDY IN ALL PATIENTS WITH ATRIAL FIBRILLATION AND BMI > 28,0 KG/M<sup>2</sup> BEFORE CATHETER ABLATION.
- PO 7 ROLE OF EPICARDIAL ADIPOSE TISSUE VOLUME AS PREDICTOR OF ATRIAL FIBRILLATION RECURRENCE
- PO 8 EVALUATING THE VALUE OF THE TIMING OF RECURRENCE DURING BLANKING PERIOD AFTER ATRIAL FIBRILLATION ABLATION

- PO 9 X-RAY AF: RESULTADOS PRINCIPAIS DO REGISTO DE FIBRILHAÇÃO AURICULAR EM PORTUGAL CONTINENTAL
- PO 10 AUTONOMIC DYSFUNCTION IS DIVERSE IN REFLEX SYNCOPE AND ATRIAL FIBRILLATION
- PO 11 PERI-PROCEDURAL, 30-DAY AND 1 YEAR-OUTCOMES IN CHRONIC DIALYSIS PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE IMPLANTATION
- PO 12 SCREENING PULMONARY HYPERTENSION IN SYSTEMIC SCLEROSIS USING CARDIOPULMONARY EXERCISE TEST
- PO 13 ACUTE CORONARY SYNDROMES IN YOUNG PEOPLE: APPLICABILITY OF THE GRACE AND CRUSADE SCORES
- PO 14 PREVALENCE AND MANAGEMENT OF CARDIOVASCULAR DISEASE IN PATIENTS WITH PRIOR RENAL TRANSPLANTATION
- PO 15 SEX DISPARITIES IN LIPID-LOWERING THERAPY AND DYSLIPIDEMIC CONTROL IN A CORONARY REHABILITATION PROGRAM
- PO 16 CLINICAL DETERMINANTS AND BARRIERS TO CARDIAC REHABILITATION ENROLMENT OF HEART FAILURE PATIENTS
- PO 17 PHYSICAL ACTIVITY AND HEART FAILURE: A FORGOTTEN INDICATOR
- PO 18 HEART FAILURE- ONE ONLY DISEASE OR A GROUP OF DIFFERENT ENTITIES?
- PO 19 HEART-KIDNEY CROSSTALK: HEART FAILURE AND THE RISK OF CARDIOVASCULAR EVENTS AND END STAGE RENAL DISEASE IN YOUNG TYPE 2 DIABETIC PATIENTS
- PO 20 LEFT BUNDLE BRANCH BLOCK - IS IT POSSIBLE TO PREDICT LEFT VENTRICLE DYSFUNCTION?
- PO 21 POSTSTERNOTOMY MEDIASTITIS - OUR 10 YEAR EXPERIENCE WITH OMENTUM FLAP SURGERY
- PO 22 QUILTY EFFECT AND ITS UNCERTAIN REPERCUSSION IN HEART TRANSPLATED PATIENTS
- PO 23 MORTALITY PREDICTORS IN INFECTIVE ENDOCARDITIS PATIENTS SUBMITTED TO SURGERY - WHAT CAN BE IMPROVED?
- PO 24 COULD CMV VIREMIA HAVE AN IMPACT ON HEART TRANSPLANT PATIENTS' HEMODYNAMICS?
- PO 25 ELECTROCARDIOGRAPHIC ASSESSMENT OF LVH IN AORTIC STENOSIS PATIENTS: HOW WELL DOES IT CORRELATE WITH MYOCARDIAL MASS?
- PO 26 COMPARISON BETWEEN THE EUROPEAN SCORE AND THE UPDATED SCORE2 FOR CARDIOVASCULAR OUTCOMES
- PO 27 RELATIONSHIP BETWEEN THE BLOOD PRESSURE AND THE LONG-TERM PROGNOSIS IN A COHORT OF CORONARY PATIENTS
- PO 28 LIPOPROTEIN(A) AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH CORONARY ARTERY DISEASE AND IMPAIRED GLUCOSE METABOLISM
- PO 29 MY PATIENT HAS A POSITIVE ISCHEMIA TEST: WILL HE HAVE OBSTRUCTIVE CORONARY ARTERY DISEASE?
- PO 30 EXERCISE ELECTROCARDIOGRAM - A DIAGNOSTIC TEST OF THE PAST?
- PO 31 PREDICTING THE LONG-TERM OUTCOME OF PATIENTS ADMITTED WITH ACUTE HEART FAILURE TO THE EMERGENCY DEPARTMENT USING RENAL MARKERS
- PO 32 HOW MUCH MORE HYPERGLYCEMIC IS MY MYOCARDIAL INFRACTION PATIENT AND WHY DOES IT MATTER?
- PO 33 SHOULD WE TRUST SCORES TO RULE OUT TRANSESOPHAGIC ECHOCARDIOGRAPHY IN PATIENTS WITH STAPHYLOCOCCUS AUREUS BACTERIEMIA?
- PO 34 CARDIAC MAGNETIC RESONANCE IN MYOCARDITIS: BESIDES THE DIAGNOSIS?
- PO 35 IMPLICATIONS OF SEPTAL LATE GADOLINIUM ENHANCEMENT IN PATIENTS WITH ACUTE MYOCARDITIS
- PO 36 TRICUSPID REGURGITATION - PATIENTS CHARACTERISTICS, TREATMENT AND OUTCOMES
- PO 37 IMPACT OF CONCOMITANT MITRAL AND TRICUSPID REGURGITATION IN PATIENTS WITH SIGNIFICANT CHRONIC AORTIC REGURGITATION
- PO 38 CLINICAL AND ECHOCARDIOGRAPHIC PREDICTORS OF WORSENING MITRAL REGURGITATION AFTER PERCUTANEOUS MITRAL VALVE REPAIR
- PO 39 COVID-19 IMPACT ON REFERRALS, TREATMENT DECISIONS AND TIME ON THE WAITING LIST FOR VALVULAR HEART DISEASE INTERVENTION
- PO 40 IS WILKINS SCORE OVER 9 A DEFINITIVE LIMIT TO FAVORABLE LONG-TERM SUCCESS IN PERCUTANEOUS VALVE COMMISSUROTOMY?
- PO 41 MANAGEMENT OF ACUTE LEFT MAIN OCCLUSION IN SURGICAL AND NON-SURGICAL CENTERS: A MULTICENTER STUDY
- PO 42 A MULTICENTER REGISTRY OF ACUTE LEFT MAIN CORONARY ARTERY OCCLUSION: DIABETES MATTERS?
- PO 43 OUTCOMES OF PATIENTS WITH ACUTE UNPROTECTED LEFT MAIN CORONARY OCCLUSION: A MULTICENTRE STUDY
- PO 44 ACUTE MYOCARDIAL INFARCTION IN PATIENTS WITH ACUTE OCCLUSION OF THE LEFT MAIN CORONARY ARTERY - DOES AGE MATTER?
- PO 45 EMERGENT CORONARY ANGIOGRAPHY IN A 90-PLUS POPULATION - OUTCOMES AT 5-YEARS FOLLOW-UP

- PO 46 PREDICTORS OF SURVIVAL AND ICD SHOCKS IN NON-ISCHEMIC CARDIOMYOPATHY PATIENTS SUBMITTED TO VENTRICULAR TACHYCARDIA ABLATION
- PO 47 THE PERI-INFARCT "GRAY ZONE" OF MYOCARDIAL FIBROSIS IS A BETTER PREDICTOR OF VENTRICULAR ARRHYTHMIAS THAN DENSE CORE FIBROSIS IN PATIENTS WITH PREVIOUS MYOCARDIAL INFARCTION
- PO 48 CORRELATION BETWEEN LEFT VENTRICLE WALL-THICKNESS BY CT AND ENDOCARDIAL POTENTIALS IN PATIENTS WITH ISCHEMIC CARDIOPATHY- A PILOT STUDY
- PO 49 BRUGADA SYNDROME: CHARACTERIZATION OF A PORTUGUESE BRUGADA SYNDROME COHORT
- PO 50 QRS DURATION AND FREQUENT PVC: ADDITIONAL FEATURES IN BRUGADA SYNDROME STRATIFICATION
- PO 51 THERAPEUTIC EFFECTS OF NEBULIZATION- BASED DELIVERY OF ANTI-MIR-146A IN EXPERIMENTAL PULMONARY ARTERIAL HYPERTENSION
- PO 52 ZNF 259C>G VARIANT RS964184 IS ASSOCIATED WITH CORONARY ARTERY DISEASE AND DYSLIPIDEMIA IN THE YOUNGER POPULATION
- PO 53 IMPACT OF EXERCISE TRAINING AND CARVEDILOL ON CARDIOVASCULAR PARAMETERS IN DOXORUBICIN TREATED RATS
- PO 54 CUMULATIVE DOXORUBICIN DOSAGE IS A TRIGGERING FACTOR FOR COGNITIVE AND PHYSIOLOGICAL DYSFUNCTION?
- PO 55 PULMONARY EMBOLISM - PLATELET INDICES' IN PATIENTS WITH OR WITHOUT RIGHT VENTRICULAR DILATATION
- PO 56 DOES BLOOD UREA NITROGEN-TO-CREATININE RATIO PREDICT OUTCOMES IN DECOMPENSATED HEART FAILURE?
- PO 57 C2HEST SCORE - HEART FAILURE RISK SCORE: PREDICTIVE VALUE FOR ONE-YEAR MORTALITY AND RE-ADMISSION AFTER DISCHARGE
- PO 58 GWTG-HF SCORE VS AHEAD SCORE: WHICH SCORES BETTER?
- PO 59 HEMODYNAMIC GAIN INDEX: A NEW PROGNOSTIC MARKER IN HEART FAILURE?
- PO 60 THE HFFI, A NEW FRAILTY INDEX FOR ASSESSING LONG-TERM OUTCOMES IN HEART FAILURE
- PO 61 PAPILLARY FIBROELASTOMAS - DIAGNOSTIC CHALLENGES AND CLINICAL AND MORPHOLOGIC FEATURES
- PO 62 CARDIAC MYXOMA EMBOLIC EVENTS: CHARACTERIZATION AND PREDICTORS
- PO 63 REDUCING THE RISK IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION - FROM GUIDELINES TO PRACTICE
- PO 64 DIASTOLIC DYSFUNCTION IN PRECAPILLARY PULMONARY HYPERTENSION - LOOKING LEFT TO SEE RIGHT
- PO 65 WHAT ARE THE NEWS IN PULMONARY EMBOLISM RISK STRATIFICATION?
- PO 66 CABG VS PCI FOR DIABETIC PATIENTS WITH NON-ST ELEVATION ACS: IN-HOSPITAL OUTCOMES
- PO 67 CABG VS PCI FOR DIABETIC PATIENTS WITH NON-ST ELEVATION ACS: ONE-YEAR OUTCOMES
- PO 68 SYMPTOMS AT NSTEMI PRESENTATION: DO PATIENT'S COMPLAINTS PREDICT THE OUTCOME?
- PO 69 BLEEDING RISK IN PATIENTS WITH NSTEMI: P2Y12 INHIBITORS PRESCRIPTION PATTERNS FROM 2019 TO 2021
- PO 70 UTILITY OF THE AGE SHOCK INDEX IN PATIENTS WITH AN ACUTE CORONARY SYNDROME
- PO 71 THE NURSE-FAMILY INTERACTION OF THE CRITICALLY ILL PERSON IN A CARDIAC INTENSIVE CARE UNIT
- PO 72 FUNCTIONAL CAPACITY ASSESSMENT OF ISCHEMIC PATIENTS AFTER ACUTE EVENT USING THE 6MWT
- PO 73 EGSYS SCORE - A USEFUL PRACTICE TOOL FOR THE PREDICTION OF REFLEX SYNCOPE?
- PO 74 EXERCISE TRAINING IN CARDIAC REHABILITATION AND CHANGES IN SELF-REPORTED HEALTH RELATED QUALITY OF LIFE
- PO 75 IMPACT OF A SYNCOPE EDUCATIONAL PREVENTION PROGRAM: A FIRST-YEAR EXPERIENCE
- PO 76 IS FLOW BETTER IN ML/M2 OR ML/S - A PRACTICAL REFLECTION ON AORTIC STENOSIS
- PO 77 LEFT VENTRICULAR REVERSE REMODELING AFTER TAVR FOR AORTIC STENOSIS
- PO 78 FLOW RATE IN SEVERE AORTIC STENOSIS - A GOOD PROGNOSTIC MARKER FOR PERCUTANEOUS VALVE IMPLANTATION?
- PO 79 LEFT VENTRICULAR REVERSE REMODELING IN POST OPERATIVE AORTIC STENOSIS PATIENTS: PREVALENCE AND PREDICTOR(S)
- PO 80 SHOULD CONTRACTILE RESERVE BE A DECISIVE FACTOR ON SEVERE AORTIC VALVE INTERVENTION?
- PO 81 NOAC IN ADULT CONGENITAL HEART DISEASE PATIENTS: A SINGLE-CENTER EXPERIENCE
- PO 82 OPTIMIZING ADULT CONGENITAL HEART DISEASE CARE: EXPERIENCE OF AN ORGANIZED PROGRAM IN A REMOTE NON SPECIALIST CENTER
- PO 83 OLD AGE IN ADULT CONGENITAL HEART DISEASE: A CONTEMPORARY REALITY
- PO 84 LONG-TERM OUTCOME IN FONTAN PROCEDURE PATIENTS: THE DESTINATION THERAPY OR A BRIDGE TO TRANSPLANT?
- PO 85 ANOMALOUS AORTIC ORIGIN OF THE RIGHT CORONARY ARTERY: SINGLE CENTRE EXPERIENCE

- PO 86 HIS BUNDLE AND LEFT BUNDLE BRANCH PACING: INITIAL EXPERIENCE
- PO 87 PULMONARY VEIN ISOLATION PLUS CAVOTRICUSPID ISTHMUS ABLATION SHOWS NO BENEFIT IN ARRHYTHMIA RECURRENCE
- PO 88 USEFULNESS OF THE PHYSIOLOGICAL VDD PACEMAKER IN ELDERLY PATIENTS WITH NORMAL SINUS RHYTHM
- PO 89 ACESSO VENOSO AXILAR PARA IMPLANTAÇÃO DE DISPOSITIVOS DE PACING - EXPERIÊNCIA DE UM CENTRO
- PO 90 IMPACT OF THE COVID-19 LOCKDOWN IN EMERGENT PACEMAKER IMPLANTATIONS
- PO 91 APPLICATION OF SYNCOPE GUIDELINES IN A CENTER WITH A TRAUMA-FOCUSED TRIAGE
- PO 92 LONG-TERM PROGNOSIS IN PATIENTS WITH ATRIOVENTRICULAR BLOCK IN ACUTE CORONARY SYNDROME
- PO 93 LOWER RATE LIMIT IN CARDIAC RESYNCHRONIZATION THERAPY-DEFIBRILLATORS: IS LOWER BETTER?
- PO 94 THE APPLICABILITY OF FAINT SCORE IN SYNCOPE STUDY AND PREDICTION OF PACEMAKER IMPLANTATION.
- PO 95 SAFETY OF SAME-DAY VS NEXT-DAY DISCHARGE AFTER CIED: A SINGLE-CENTER EXPERIENCE
- PO 96 LEVOSIMENDAN IN OUTPATIENTS WITH ADVANCED HEART FAILURE: SINGLE-CENTER EXPERIENCE OF 200 INTERMITTENT PERFUSIONS
- PO 97 SACUBITRIL-VALSARTAN: THE EARLIER, THE BETTER?
- PO 98 PREDICTORS OF SACUBITRIL-VALSARTAN TARGET DOSE ACHIEVEMENT IN A REAL-WORLD POPULATION
- PO 99 MAXIMUM DOSE SACUBITRIL/VALSARTAN IN THE ELDERLY PEOPLE WITH HEART FAILURE AND REDUCED EJECTION FRACTION.
- PO 100 THE NEED FOR DIURETIC THERAPY IN SPITE OF HEART FAILURE WITH REDUCED EJECTION FRACTION FOUNDATIONAL THERAPY: A NEW MARKER OF ADVERSE PROGNOSIS?
- PO 101 FAMILIAL HYPERCHOLESTEROLEMIA IN ACUTE CORONARY SYNDROME PATIENTS: UNDERDIAGNOSIS IN FEMALE AND IN YOUNG PATIENTS
- PO 102 LDL-CHOLESTEROL LEVELS AFTER ACUTE CORONARY SYNDROME: 24-MONTHS VARIATIONS AND IMPACT ON OUTCOMES
- PO 103 HIGH SALT INTAKE IS A RISK FACTOR FOR KIDNEY FAILURE/MICROALBUMINURIA IN HYPERTENSIVE PATIENTS
- PO 104 REAL-WORLD ASSESSMENT OF IPCSK9 TREATMENT ADHERENCE, EFFECTIVENESS, AND TOLERABILITY: A PRELIMINARY ANALYSIS
- PO 105 DOES IT MAKE SENSE TO USE QUESTIONNAIRES TO ASSESS THE CARDIOVASCULAR RISK OF HYPERTENSIVE PATIENTS?
- PO 106 PHYSICAL EXERCISE ACTIVITY TRENDS IN ACUTE MYOCARDIAL INFARCTION PATIENTS - WHERE DO WE STAND?
- PO 107 DO PATIENTS WITH CARDIOVASCULAR RISK FACTORS REALIZE WHAT IS AT RISK?
- PO 108 CORONARY RESTENOSIS: SEVENTEEN YEARS SUMMARIZED...
- PO 109 DELAY BETWEEN SYMPTOMS ONSET AND SEEKING MEDICAL CARE - DOES INITIAL RHYTHM PLAYS A ROLE?
- PO 110 SHOULD WE STAY OR SHOULD WE GO: ASSESSMENT OF THE NEED FOR THE IMPLANTATION OF A DEFINITE PACEMAKER IN A POPULATION OF ACUTE CORONARY SYNDROME THAT EVOLVED IN ADVANCED ATRIOVENTRICULAR BLOCK.
- PO 111 BALLOON PULMONARY ANGIOPLASTY IN CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION: WHO BENEFITS THE MOST?
- PO 112 RESIDUAL SYNTAX SCORE IN TAVR PATIENTS
- PO 113 SMALL-BORE ASPIRATION THROMBECTOMY VERSUS CATHETER-DIRECTED THROMBOLYSIS IN INTERMEDIATE-HIGH RISK ACUTE PULMONARY EMBOLISM
- PO 114 RADIATION IN THE CATH LAB: ARE PATIENTS REALLY SAFE?
- PO 115 CONTRAST-INDUCED NEPHROPATHY FOLLOWING PCI: CAN WE CALCULATE A SAFE CONTRAST VOLUME?
- PO 116 NORMAL FLOW, LOW GRADIENT AORTIC STENOSIS - IS LVOT THE DETERMINANT?
- PO 117 AORTIC STENOSIS - THE LUNG IS OFTEN OVERLOADED, BUT WHAT ABOUT THE LIVER?
- PO 118 AORTIC VALVE CALCIUM SCORE AND PERI-PROTHESIS LEAKS AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION: IS THERE A HINT?
- PO 119 TAVI - MULTIDIMENSIONAL EARLY BENEFITS ON ELDERLY PATIENTS
- PO 120 PREVALENCE, MANAGEMENT, AND PROGNOSIS OF PATIENTS WITH SEVERE AORTIC STENOSIS AND REDUCED EJECTION FRACTION
- PO 121 PROGNOSTIC SIGNIFICANCE OF PEAK ATRIAL LONGITUDINAL STRAIN IN PATIENTS WITH FUNCTIONAL MITRAL REGURGITATION
- PO 122 IDENTIFICATION OF HIGH-RISK PATIENTS WITH NON-ST SEGMENT ELEVATION ACUTE CORONARY SYNDROMES USING STRAIN ANALYSIS

- PO 123 QUANTITATIVE LONGITUDINAL PEAK SYSTOLIC STRAIN IN THE DETECTION OF LEFT VENTRICULAR WALL MOTION ABNORMALITIES: AN ANALYSIS OF OUR DAILY ECHOCARDIOGRAPHIC PRACTICE
- PO 124 PROGNOSTIC VALUE OF EXERCISE STRESS ECHOCARDIOGRAPHY IN PATIENTS WITH KNOWN CORONARY ARTERY DISEASE
- PO 125 MITRAL REGURGITATION ON LOW-FLOW LOW-GRADIENT SEVERE AORTIC STENOSIS AND PRESERVED EJECTION FRACTION
- PO 126 RELATIVE APICAL LONGITUDINAL STRAIN - A POWERFUL TOOL TO PREDICT LONG-TERM OUTCOMES IN TRANSTHYRETIN AMYLOID CARDIOMYOPATHY PATIENTS
- PO 127 CHRONOTROPIC INCOMPETENCE AND ITS RELATION TO EXERCISE CAPACITY IN HYPERTROPHIC CARDIOMYOPATHY
- PO 128 COMPARISON OF LEFT VENTRICULAR STRAIN OBTAIN BY CARDIAC MAGNETIC RESONANCE 3D FEATURE TRACKING AND 3D SPECKLE TRACKING ECHOCARDIOGRAPHY, IN HYPERTROPHIC CARDIOMYOPATHY
- PO 129 CORONARY FLOW VELOCITY RESERVE IN HYPERTROPHIC CARDIOMYOPATHY: RELATION WITH NONUNIFORM MYOCARDIAL HYPERTROPHY
- PO 130 SIGNALLING AMYLOIDOSIS DIAGNOSIS WITH RED FLAGS
- PO 131 OUTCOMES OF PATIENTS ENROLLED IN A PHASE 2 CARDIAC REHABILITATION PROGRAM ACCORDING TO ACUTE CORONARY SYNDROME
- PO 132 CARDIAC REHABILITATION AFTER ELECTIVE HEART SURGERY: A VALVULAR SURGERY FOCUSED COMPARISON TO CORONARY ARTERY BYPASS GRAFTING
- PO 133 THE RISE OF THE DIGITAL ERA IN CARDIAC REHABILITATION: CAN IT KEEP UP WITH THE PRESENTIAL MODEL?
- PO 134 SHORTER CARDIAC REHABILITATION PROGRAMS: TAKING TIME IS TAKING EFFECTIVENESS?
- PO 135 CARDIAC REHABILITATION PROGRAMS: DOES SHORTER COURSE TRANSLATE INTO LESS EXERCISE CAPACITY?
- PO 136 PATIENTS ADMITTED WITH ACUTE HEART FAILURE AT AN INTENSIVE CARE DEPARTMENT - COMPARISON BETWEEN THE CLINICAL PROFILES OF PATIENTS WITH PRESERVED VS. REDUCED LEFT VENTRICULAR EJECTION FRACTION
- PO 137 EVALUATION OF RV-ARTERIAL COUPLING IN ADVANCED HEART FAILURE
- PO 138 RESPONSE AND LONG-TERM OUTCOMES WITH RESYNCHRONIZATION THERAPY: DOES HEART FAILURE ETIOLOGY MATTER?
- PO 139 PROGNOSTIC IMPACT OF RIGHT VENTRICULAR FUNCTION IN ADVANCED HEART FAILURE
- PO 140 FUNCTIONAL MITRAL REGURGITATION IN ADVANCED HEART FAILURE
- PO 141 CARDIOVASCULAR OUTCOMES ACCORDING TO RISK CATEGORY: RESULTS OF A RETROSPECTIVE DATABASE STUDY
- PO 142 DO ATHEROSCLEROTIC EVENTS CHANGE LIPID LOWERING THERAPY USE IN CLINICAL PRACTICE?THE ANSWER WITH RWE
- PO 143 URIC ACID AS A RISK FACTOR FOR CARDIOVASCULAR DISEASE AND MORTALITY
- PO 144 IMPORTANCE OF A GENETIC SCORE IN ASSESSING THE RISK OF ARTERIAL STIFFNESS
- PO 145 ANTITHROMBOTIC STRATEGIES AFTER LAA OCCLUSION - IS THERE A WINNING STRATEGY?
- PO 146 THE IMPACT OF OUTPATIENT EMERGENCY MEDICAL SYSTEM IN STEMI PATIENTS UNDERGOING PRIMARY ANGIOPLASTY: A SINGLE-CENTRE EXPERIENCE
- PO 147 AT THE OUTER EDGE OF STEMI TIME: EVEN AFTER 12 HOURS, THE CLOCK KEEPS TICKING.
- PO 148 STEMI TREATMENT IN REMOTE LOCATIONS: AN UNCOMMON REALITY
- PO 149 THE OBESITY PARADOX IN ACUTE ST-ELEVATED MYOCARDIAL INFARCTION
- PO 150 IS SYMPTOMS-BALLOON-TIME A BETTER PROGNOSTIC PREDICTOR?
- PO 151 PERCUTANEOUS PATENT FORAMEN OVALE CLOSURE: 18 YEARS' EXPERIENCE IN A TERTIARY CENTRE
- PO 152 PERMANENT PACEMAKER IMPLANTATION AFTER ALCOHOLIC SEPTAL ABLATION: LONG-TERM OUTCOMES
- PO 153 LEFT ATRIAL APPENDAGE OCCLUSION IN PATIENTS WITH CHRONIC KIDNEY DISEASE OR CANCER: AN INTELLIGENT CHOICE?
- PO 154 LEFT ATRIAL APPENDAGE OCCLUSION IS AN EFFECTIVE AND SAFE STRATEGY FOR LONG TERM PREVENTION OF STROKE OR SYSTEMIC EMBOLISM
- PO 155 IS REAL WORLD PATENT FORAMEN OVALE CLOSURE A SAFE AND EFFECTIVE STRATEGY?
- PO 156 PULMONARY THROMBOEMBOLISM: IS B-TYPE NATRIURETIC PEPTIDE AN EARLIER RISK MARKER?
- PO 157 ELECTROCARDIOGRAPHIC SCORE IN PREDICTING DIAGNOSIS AND SEVERITY OF PULMONARY EMBOLISM
- PO 158 COMPARISON OF DIFFERENT DIAGNOSTIC MODELS PERFORMANCE IN PATIENTS WITH COVID-19 AND PULMONARY EMBOLISM

- PO 159 AGE-DEPENDENCE PERFORMANCE OF DIAGNOSTIC PREDICTION RULES FOR PULMONARY EMBOLISM
- PO 160 ECHOCARDIOGRAPHIC DATA IN ACUTE PULMONARY EMBOLISM - WHAT IS THE PROGNOSTIC VALUE IN THE REAL WORLD?
- PO 161 CHARACTERIZATION OF RISK FACTORS AND MORTALITY IN YOUNG PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
- PO 162 GENDER DISPARITIES IN ACUTE MYOCARDIAL INFARCTION - STILL AN UNSOLVED PUZZLING ISSUE
- PO 163 MACE IN MYOCARDIAL INFARCTION WITH NON-OBSTRUCTIVE CORONARY ARTERIES: PREDICTORS AND PROGNOSIS
- PO 164 DISCRIMINATORY CAPACITY OF ACTION-ICU ACCORDING TO AGE - A SCORE FOR ALL?
- PO 165 FINDING TAKOTSUBO CARDIOMYOPATHY ON CARDIAC MAGNETIC RESONANCE
- PO 166 EFFECT OF SACUBITRIL/VALSARTAN ON VENTRICULAR ARRHYTHMIA BURDEN IN HEART FAILURE WITH REDUCED EJECTION FRACTION
- PO 167 TELEMONITORING IN HEART FAILURE MANAGEMENT - THE EXPERIENCE OF A REMOTE CENTER
- PO 168 THE EFFECTS OF SACUBITRIL-VALSARTAN ON ICD INDICATION IN PATIENTS WITH HEART FAILURE
- PO 169 VENTRICULAR TACHYCARDIA ABLATION IN NON-ISCHEMIC CARDIOMYOPATHY
- PO 170 PRIMARY PREVENTION IMPLANTATION OF CARDIOVERTER DEFIBRILLATORS IN TRULY ASYMPTOMATIC PATIENTS - SHOULD WE RETHINK CURRENT RECOMMENDATIONS?
- PO 171 PREDICTORS OF IN-HOSPITAL LEFT VENTRICLE FUNCTION RECOVERY IN TAKOTSUBO SYNDROME
- PO 172 TAKOTSUBO SYNDROME: TEN-YEAR EXPERIENCE FROM A SINGLE CENTER
- PO 173 TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM): A POTENTIAL ROLE FOR CARDIOPULMONARY EXERCISE TESTING
- PO 174 TRANSTHYRETIN CARDIAC AMYLOIDOSIS DUE TO RARE MUTATIONS IN PORTUGUESE PATIENTS
- PO 175 SPONGY MYOCARDIUM OR LEFT VENTRICULAR NONCOMPACTION: WHICH FACTORS IMPACT PROGNOSIS?
- PO 176 HYPERKALEMIA AND HEART FAILURE WITH REDUCED EJECTION FRACTION: PREVALENCE AND PROGNOSTIC IMPACT ON A PORTUGUESE POPULATION
- PO 177 SERUM URIC ACID LEVELS PROGNOSTIC VALUE IN CHRONIC HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION
- PO 178 IRON STATUS VARIATION IN ACUTE HEART FAILURE: A PROSPECTIVE STUDY - RELEASE OF PRELIMINARY DATA
- PO 179 HIGH PREVALENCE OF POLYCYTHEMIA IN HEART FAILURE PATIENTS
- PO 180 PLASMA VOLUME VARIATION AND GLOMERULAR FILTRATION RATE IN HEART FAILURE ADMISSIONS
- PO 181 EXERCISE TRAINING IMPROVES CARDIORESPIRATORY FITNESS IN HEART FAILURE PATIENTS: A LOOK BEYOND PEAK OXYGEN CONSUMPTION
- PO 182 VALUE OF CARDIOPULMONARY EXERCISE TEST SUBMAXIMAL PARAMETERS IN THE ASSESSMENT OF AORTIC STENOSIS PATIENTS
- PO 183 CARDIAC OPTIMAL POINT: IDENTIFYING HIGH RISK PATIENTS FOR AN OPTIMAL APPROACH
- PO 184 VERY ACUTE BENEFITS ON PHYSICAL PERFORMANCE IN ELDERLY PATIENTS WHO UNDERGONE TAVI
- PO 185 TREADMILL TESTING AND PROGNOSIS: ARE WE LOOKING AT THE RIGHT THINGS?
- PO 186 CHRONOTROPIC INCOMPETENCE- STILL A SUITABLE INDICATOR?
- PO 187 ACUTE KIDNEY INJURY ON ADMISSION FOR ACUTE CORONARY SYNDROME AS A PREDICTOR OF 1-YEAR MORTALITY
- PO 188 MODIFIED M-CHA2DS2-VASC SCORE PREDICTS MORTALITY AT EMERGENCY DEPARTMENT ADMISSION IN COVID-19 PATIENTS
- PO 189 C-REACTIVE PROTEIN AS A PROGNOSTIC MARKER IN MYOCARDIAL INFARCTION WITH NON-OBSTRUCTIVE CORONARY ARTERIES
- PO 190 PERFORMANCE OF DIFFERENT HIGH SENSITIVITY CARDIAC TROPONIN ASSAYS IN PATIENTS WITH SUSPECTED ACUTE CORONARY SYNDROME
- PO 191 IMPACT OF THE USE OF CUSP OVERLAP PROJECTION TECHNIQUE IN THE INCIDENCE OF POST-TAVR PERMANENT PACEMAKER IMPLANTATION WITH SELF-EXPANDING VALVES
- PO 192 PREDICTORS OF FUNCTIONAL RECOVERY AFTER PERCUTANEOUS AORTIC VALVE IMPLANTATION - DATA FROM 459 CASES
- PO 193 BLEEDING AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION - WHAT ARE THE OUTCOMES AND HOW CAN WE PREDICT IT
- PO 194 IS ILIOFEMORAL CALCIUM VOLUME ASSOCIATED WITH VASCULAR AND BLEEDING COMPLICATIONS AFTER TAVI?

- PO 195 CONTEMPORARY MANAGEMENT AND OUTCOMES OF PATIENTS WITH VASCULAR COMPLICATIONS DURING TRANSFEMORAL TAVI.
- PO 196 ENDOCARDITIS IN-HOSPITAL MORTALITY: WHAT CAN WE EXPECT?
- PO 197 INFECTIVE ENDOCARDITIS: EXPERIENCE OF THE LAST 20 YEARS
- PO 198 INFECTIVE ENDOCARDITIS: HAS ITS PROGNOSIS CHANGED 5 YEARS AFTER THE NEW ESC GUIDELINES?
- PO 199 PREDICTORS OF IN-HOSPITAL MORTALITY IN INFECTIOUS ENDOCARDITIS
- PO 200 PREDICTORS OF RECURRENCE IN INFECTIOUS ENDOCARDITIS
- PO 201 MYOCARDIAL INFARCTION IN THE ABSENCE OF OBSTRUCTIVE CORONARY ARTERY DISEASE - CARDIAC MAGNETIC RESONANCE USE IN IDENTIFYING THE UNDERLYING CAUSES
- PO 202 QUANTITATIVE COMPARISON BETWEEN 2D VERSUS 3D LATE GADOLINIUM ENHANCEMENT FOR MYOCARDIAL SCAR CHARACTERIZATION - POSSIBLE IMPLICATION FOR INTERVENTION GUIDANCE AND ARRHYTHMOGENIC RISK ASSESSMENT
- PO 203** LEFT VENTRICULAR MECHANICS IN PATIENTS WITH LEFT BUNDLE BRANCH BLOCK ASSESSED BY CARDIAC MAGNETIC RESONANCE – INFLUENCE OF ETIOLOGY AND PRESENCE OF FIBROSIS
- PO 204 VENTRICULAR ARRHYTHMIA IN PATIENTS WITH NORMAL ECHOCARDIOGRAPHY - CAN CARDIOVASCULAR MAGNETIC RESONANCE ENHANCE THE DIAGNOSIS OF STRUCTURAL HEART DISEASE?
- PO 205 SEEING BEYOND PERFUSION - IS THERE A ROLE FOR OTHER HIGH-RISK ISCHEMIA MARKERS IN PATIENTS WITH NORMAL PERFUSION ON SPECT MYOCARDIAL PERFUSION IMAGING?
- PO 206 LONG-TERM IMPACT OF ACTIVATION CIRCUIT-BASED VENTRICULAR TACHYCARDIA ABLATION ON VENTRICULAR ARRHYTHMIA BURDEN
- PO 207 FOLLOW-UP OF SUSTAINED VENTRICULAR TACHYCARDIA IN ACUTE CORONARY SYNDROMES
- PO 208 EFFICACY OF MEXILETINE IN THE TREATMENT OF PATIENTS WITH RECURRENT VENTRICULAR ARRHYTHMIAS IN LONG-TERM FOLLOW-UP
- PO 209 IDIOPATHIC VENTRICULAR ARRHYTHMIA ABLATION - A CENTER EXPERIENCE
- PO 210 VENTRICULAR TACHYCARDIA ABLATION IN PATIENTS WITH ISCHAEMIC AND NON-ISCHAEMIC CARDIOMYOPATHY
- PO 211 INITIAL EXPERIENCE OF ATRIAL FIBRILLATION CATHETER ABLATION IN A LOW-VOLUME CENTER: CRYOABLATION VS RADIOFREQUENCY
- PO 212 IMPACT OF INDUCED ATRIAL FIBRILLATION DURING ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA ABLATION
- PO 213 SCREENING STRATEGIES FOR ATRIAL FIBRILLATION IN THE ELDERLY POPULATION: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
- PO 214 VITAMIN-K ANTAGONISTS VERSUS NON-VITAMIN K ORAL ANTICOAGULANTS IN ELDERLY PATIENTS WITH SEVERE AORTIC STENOSIS AND ATRIAL FIBRILLATION
- PO 215 RESPIRATORY DISTURBANCE INDEX AS A PREDICTOR OF ATRIAL FIBRILLATION
- PO 216 DAPAGLIFLOZIN IN HEART FAILURE WITH REDUCED EJECTION FRACTION: A RANDOMIZED CONTROLLED TRIAL
- PO 217 IMPACT OF SGLT2 INHIBITORS ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
- PO 218 SGLT2 INHIBITORS IN HEART FAILURE WITH REDUCED EJECTION FRACTION: THEIR BIOLOGICAL PROPERTIES GOES WELL BEYOND A SMART DIURETIC EFFECT
- PO 219 SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS: THE GLUE FOR HEART FAILURE WITH REDUCED EJECTION FRACTION FOUNDATIONAL THERAPY
- PO 220 DAPAGLIFOZIN IN THE REAL WORLD - WHAT IS THE IMPACT ON HEART FAILURE WITH REDUCED EJECTION FRACTION ALREADY UNDER OPTIMIZED THERAPY?
- PO 221 CAN WE COUNT ON ECHOCARDIOGRAPHY TO IDENTIFY DIFFERENT TYPES OF CARDIAC AMYLOIDOSIS?
- PO 222 AN ECHOCARDIOGRAPHIC INSIGHT ON POST-COVID-19 SYMPTOMS.
- PO 223 CLINICAL AND ECHOCARDIOGRAPHIC FEATURES OF PLATYPNEA-ORTHODEOXIA SYNDROME: A SINGLE-CENTRE EXPERIENCE
- PO 224 PROGNOSTIC VALUE OF MITRAL ANNULAR PLANE SYSTOLIC EXCURSION IN PATIENTS WITH ACUTE CORONARY SYNDROME AND PRESERVED EJECTION FRACTION.
- PO 225 LONG TERM LEFT VENTRICULAR IMPAIRMENT AFTER SARS-COV2 INFECTION
- PO 226 PREDICTORS OF DYSRHYTHMIAS IN COVID-19 INTENSIVE CARE PATIENTS AND IMPACT ON IN-HOSPITAL MORTALITY
- PO 227 MYOCARDITIS AND PERICARDITIS FOLLOWING COVID-19 VACCINATION IN ADOLESCENTS

- PO 228** THROMBOEMBOLIC EVENTS IN THE FOLLOW UP OF COVID-19 PATIENTS
- PO 229** COMPARISON OF 5 ACUTE PULMONARY EMBOLISM MORTALITY RISK SCORES IN PATIENTS WITH COVID-19
- PO 230** IS STANDARD CARDIAC EVALUATION ENOUGH FOR COVID-19 PATIENTS WITH SEVERE DISEASE?
- PO 231** LEFT MAIN ARTERY LESIONS- THE ROLE OF IVUS AND CORONARY PHYSIOLOGY
- PO 232** PERCUTANEOUS CORONARY INTERVENTION IN ELDERLY PATIENTS WITH CHRONIC KIDNEY DISEASE AND NON-ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME - IS IT WORTH IT?
- PO 233** PCI OF CHRONIC TOTAL OCCLUSIONS: WHAT IS THE CLINICAL BENEFIT AND IMPACT ON QUALITY OF LIFE?
- PO 234** PCI OF LEFT MAIN CORONARY ARTERY: REAL LIFE VS CLINICAL TRIALS OUTCOME RESULTS
- PO 235** STENT STRATEGIES IN DISTAL LEFT MAIN LESIONS: THE SIMPLER, THE BETTER?
- PO 236** TRANS-SUBCLAVIAN TRANSCATHETER AORTIC VALVE IMPLANTATION: THE SECOND-LINE ACCESS
- PO 237** PERCUTANEOUS TRICUSPID VALVE INTERVENTION - EARLY EXPERIENCE IN A SINGLE CENTRE
- PO 238** CLINICAL OUTCOMES OF TRANSCATHETER AORTIC VALVE IMPLANTATION IN YOUNGER PATIENTS
- PO 239** EARLY AORTIC VALVE REPLACEMENT IN ASYMPTOMATIC SEVERE AORTIC STENOSIS WITH PRESERVED EJECTION FRACTION
- PO 240** BIVALVE: PROCEDURAL AND MID-TERM RESULTS IN PATIENTS WITH AORTIC STENOSIS TREATED WITH IMPLANTATION OF 2 (IN-SERIES) PROSTHESES IN A SINGLE PROCEDURE
- PO 241** PREDICTORS OF CARDIOTOXICITY IN PATIENTS WITH BREAST CANCER: A PROSPECTIVE STUDY
- PO 242** SHANGHAI SCORING SYSTEM FOR RISK STRATIFICATION IN A PORTUGUESE SAMPLE OF BRUGADA SYNDROME PATIENTS
- PO 243** IS NON-VITAMIN K ORAL ANTICOAGULANTS SAFE IN ADULT CONGENITAL HEART DISEASE
- PO 244** PREDICTORS OF PACEMAKER DEPENDENCY AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT
- PO 245** THE VALUE OF ADMISSION NT-PROBNP IN PROGNOSIS OF PATIENTS HOSPITALIZED WITH COVID-19 AND WITHOUT HISTORY OF HEART FAILURE.
- PO 246** CAD IN KIDNEY TRANSPLANT RECIPIENTS: A REAL-WORLD ASSESSMENT PRE-ISCHEMIA-CKD